🔎 Trials Near Me

Home › Schizophrenia › NCT03794076

Cromoglicate Adjunctive Therapy for Outpatients With Schizophrenia

RecruitingPhase 1/2

Cromoglicte Adjunctive Therapy for Outpatients With Schizophrenia

Who can join

Ages 18 to 65 · All sexes

Full eligibility criteria
Inclusion Criteria:

* Written informed consent.
* Both genders, ages 18-60 years
* Schizophrenia / schizoaffective disorder (DSM V).
* Treated with the same APD for at least 60 days; Stable dose of APD for \> 1 month, continued throughout the study.
* PANSS total score of 60 and Score 4 or more on one or more items of the 'positive' syndrome items (P1-P7)
* Preference for patients with duration of psychosis less than 7 years.

Exclusion Criteria:

* No illicit substance use in last 30 days/no dependence in 6 months with the exception of methadone treatment for opioid withdrawal.
* History or current medical /neurological illnesses that may lead to an unstable course with the exception of epilepsy which is well-controlled on an antiepileptic medication for at least 6 months.
* Pregnancy.
* History of immune disorders, HIV infection, or receiving immune-suppressants or immuno-modulators, e.g., steroids.
* Current or prior treatment with CGY or History of hypersensitivity to CGY.
* Intellectual disability as defined in DSM V.

About the study

This is a double blind adjunctive randomized controlled trial for schizophrenia using cromoglicate.

What is being tested

Sponsor: Vishwajit Nimgaonkar, MD PhD · Participants: 160 · Started: Apr 1, 2019

Contact the study team

Official record on ClinicalTrials.gov — NCT03794076

Locations in the U.S.

PennsylvaniaUniversity of Pittsburgh, Pittsburgh

Conditions

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.